15 results on '"Taechakraichana N"'
Search Results
2. Validation of the Thai Osteoporosis Foundation and Royal College of Orthopaedic Surgeons of Thailand Clinical Practice Guideline for bone mineral density measurement in postmenopausal women
- Author
-
Suwan, A., Panyakhamlerd, K., Chaikittisilpa, S., Jaisamrarn, U., Hawanond, P., Chaiwatanarat, T., Tepmongkol, S., Chansue, E., and Taechakraichana, N.
- Published
- 2015
- Full Text
- View/download PDF
3. A blinded comparison of patient treatments to therapeutic options presented by an artificial intelligence-based clinical decision-support system
- Author
-
Suwanvecho, S., primary, Suwanrusme, H., additional, Jirakulaporn, T., additional, Taechakraichana, N., additional, Lungchukiet, P., additional, Thanakarn, N., additional, Decha, W., additional, Boonpakdee, W., additional, Preininger, A., additional, Dankwa-Mullan, I., additional, Solomon, M., additional, Wang, S., additional, Jackson, G., additional, Patel, V., additional, Shortliffe, E.H., additional, and Kiatikajornthada, N., additional
- Published
- 2019
- Full Text
- View/download PDF
4. 1435P - A blinded comparison of patient treatments to therapeutic options presented by an artificial intelligence-based clinical decision-support system
- Author
-
Suwanvecho, S., Suwanrusme, H., Jirakulaporn, T., Taechakraichana, N., Lungchukiet, P., Thanakarn, N., Decha, W., Boonpakdee, W., Preininger, A., Dankwa-Mullan, I., Solomon, M., Wang, S., Jackson, G., Patel, V., Shortliffe, E.H., and Kiatikajornthada, N.
- Published
- 2019
- Full Text
- View/download PDF
5. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial
- Author
-
Cauley, J. a., Dennis, Black, Steven, Boonen, Cummings, Steven R., Peter, Mesenbrink, Lisa, Palermo, Zulema, Man, Peyman, Hadji, Horizon Pivotal Fracture Group Horowitz, Reid Ir Z., Orloff, J., Black, D., Cummings, S., Delmas, P., Eastell, R., Reid, Ian R., Boonen, S., Cauley, J., Cosman, F., Lakatos, P., Leung, P. c., Man, Z., Lau, E., Jasqui, S., Mautalen, C., Rosario Jansen, T., Caminis, J., Eriksen, E. f., Mesenbrink, P., Raisz, L., Bauer, P., Compston, J., Demets, D., Hirschberg, R., Johnell, O., Ralston, S., Wallace, R., Farkough, M., Flood, M., Bauer, D., Palermo, L., Lang, T., Kerzberg, E., Ridruejo, M., Tate, G., Velasco, J., Hooper, M., Kotowicz, M., Nash, P., Prince, R., Roberts, A., Sambrook, P., Dobnig, H., Finkenstedt, G., Hoefle, G., Klaushofer, K., Pecherstorfer, M., Peichl, P., Body, J., Devogelaer, J. p., Geusens, P., Kaufman, J., Brenol, J., Kochen, J., Lederman, R., Radominski, S., Szejnfeld, V., Zerbini, C., Adachi, J., Brown, J., Choquette, D., Hanley, D., Josse, R., Kendler, D., Kremer, R., Morin, F., Olszynski, W., Papaioannou, A., Kinyuen, C., Chen, B., Lin, S., Casas, N., Chalem, M., Jaller, J., Molina, J., Aro, H., Heikkinen, J., Kroger, H., Makinen, L., Saltevo, J., Salmi, J., Valimaki, M., Benhamou, C. l., Fardellone, P., Werhya, G., Allolio, B., Felsenberg, D., Happ, J., Hartard, M., Hensen, J., Kaps, P., Kekow, J., Moericke, R., Ortloff, B., Schneider, P., Wassenberg, S., Balogh, A., Gomor, B., Hidvegi, T., Koranyi, L., Poor, G., Tulassay, Z., Pollak, R. d., Eshed, V., Foldes, A. j., Ish Shalom, S., Vered, I., Weiss, M., Adami, S., Barone, A., Bianchi, G., Giannini, S., Isaia, G. c., Luisetto, G., Minisola, Salvatore, Molea, N., Nuti, R., Ortolani, S., Passeri, M., Rubinacci, A., Seriolo, B., Sinigaglia, L., Choi, W. h., Kang, M. i., Kim, G. s., Kim, H. s., Kim, Y. k., Lim, S. k., Son, H. y., Yoon, H. k., Abud, C., Garcia, P., Ochoa, L., Orozco, J., Santos, J., Reid, I., Elle, S., Halse, J., Høiseth, A., Olav, H., Røed, H. i., Skag, A., Stakkestad, J., Syversen, U., Badurski, J., Czerwinski, E., Lorenc, R., Marcinowska Suchowierska, E., Sawicki, A., Supronik, J., Ailamazyan, E., Benevolenskaya, L., Dreval, A., Dvoretsky, L., Dyomina, R., Mazurov, V., Melnichenko, G., Mkrtoumyan, A., Orlov Morozov, A., Ostroumova, O., Pikhlak, E., Shemerovskaya, T., Shostak, N., Skripnikova, I., Smetnik, V., Tsyrlina, E., Usova, G., Zalevskaya, A., Zazerskaya, I., Zotkin, E., Ljunggren, O., Lofgren, J., Palmer, M., Saaf, M., Stenstrom, M., Hasler, P., Lamy, O., Lippuner, K., Merlin, C., Rizzoli, R., Theiler, R., Tyndall, A., Uebelhart, D., Chen, J. f., Chen, P. q., Chin, L. s., Hwang, J. s., Yang, T. s., Jirapinyo, M., Sattaya, R., Sriussadaporn, S., Supasin, S., Taechakraichana, N., Wilawan, K., Donnachie, H., Fraser, W., Mclellan, A., Reid, D., Abruzzo, J., Ackerman, R., Adler, R., Aloia, J., Birbara, C., Bode, B., Bone, H., Brandon, D., Dionne, D., Jr Downs, R., Dreyfus, J., Elinoff, V., Emkey, R., Fanciullo, J., Fiske, D., Genaro, P., Gollapudi, M., Gordon, R., Hennessey, J., Howard, P., Johnson, K., Johnston, C., Kagan, R., Kafka, S., Kaine, J., Klein, T., Koltun, W., Leboff, M., Levine, B., Lewiecki, E. m., Lewis, C. e., Licata, A., Lillestol, M., Lubin, B., Malamet, R., Mangione, A., Matkovic, V., Mehta, D., Miller, P., Miller, S., Murphy, F. t., Nattrass, S., Podlecki, D., Recknor, C., Rosen, C., Rowe, D., Rude, R., Schnitzer, T., Sherrer, Y., Silverman, S., Stephenson, K., Troupin, B., Tucci, J., Villareal, R., Watts, N., Weinstein, R., Weitz, M., and White, R.
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Osteoporosis ,Bed rest ,Placebo ,Drug Administration Schedule ,Article ,law.invention ,postmenopausal osteoporosis ,zoledronic acid ,Randomized controlled trial ,Risk Factors ,law ,Back pain ,disability ,fracture ,Internal medicine ,Prevalence ,Humans ,Medicine ,Disabled Persons ,Orthopedics and Sports Medicine ,Probability ,Bone Density Conservation Agents ,Diphosphonates ,business.industry ,Imidazoles ,medicine.disease ,Back Pain ,Female ,Multivariate Analysis ,Spinal Fractures ,Bed Rest ,Low back pain ,Surgery ,Zoledronic acid ,Relative risk ,medicine.symptom ,business ,medicine.drug - Abstract
The objective of this study was to determine the effect of once-yearly zoledronic acid on the number of days of back pain and the number of days of disability (ie, limited activity and bed rest) owing to back pain or fracture in postmenopausal women with osteoporosis. This was a multicenter, randomized, double-blind, placebo-controlled trial in 240 clinical centers in 27 countries. Participants included 7736 postmenopausal women with osteoporosis. Patients were randomized to receive either a single 15-minute intravenous infusion of zoledronic acid (5 mg) or placebo at baseline, 12 months, and 24 months. The main outcome measures were self-reported number of days with back pain and the number of days of limited activity and bed rest owing to back pain or a fracture, and this was assessed every 3 months over a 3-year period. Our results show that although the incidence of back pain was high in both randomized groups, women randomized to zoledronic acid experienced, on average, 18 fewer days of back pain compared with placebo over the course of the trial (p = .0092). The back pain among women randomized to zoledronic acid versus placebo resulted in 11 fewer days of limited activity (p = .0017). In Cox proportional-hazards models, women randomized to zoledronic acid were about 6% less likely to experience 7 or more days of back pain [relative risk (RR) = 0.94, 95% confidence interval (CI) 0.90–0.99] or limited activity owing to back pain (RR = 0.94, 95% CI 0.87–1.00). Women randomized to zoledronic acid were significantly less likely to experience 7 or more bed-rest days owing to a fracture (RR = 0.58, 95% CI 0.47–0.72) and 7 or more limited-activity days owing to a fracture (RR = 0.67, 95% CI 0.58–0.78). Reductions in back pain with zoledronic acid were independent of incident fracture. Our conclusion is that in women with postmenopausal osteoporosis, a once-yearly infusion with zoledronic acid over a 3-year period significantly reduced the number of days that patients reported back pain, limited activity owing to back pain, and limited activity and bed rest owing to a fracture.
- Published
- 2011
6. PMS7 A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN: A COMPARISON OF SEVEN TREATMENT OPTIONS
- Author
-
Pongchaiyakul, C, primary, Songpattanasilp, T, additional, and Taechakraichana, N, additional
- Published
- 2010
- Full Text
- View/download PDF
7. Effects of Oral Multi-Vitamin Multi-Mineral Supplement Formulations on Laboratory Outcomes and Quality of Life: A Quasi-Experimental Study.
- Author
-
Jittat N, Pongpirul K, Tepwituksakit B, Iammaleerat P, Heath J, Lungchukiet P, Taechakraichana N, and Charukitpipat A
- Abstract
Background: Multi-vitamin multi-mineral (MVMM) products often come in several single-substance capsules from different manufacturers. However, attempts to mix several vitamins and minerals into one MVMM product have been complicated and often involve legal concerns. This study aimed to comparatively investigate the changes in laboratory parameters and the quality of life (QOL) among individuals who received different MVMM formulations., Methods: This three-arm non-randomized controlled trial was conducted at VitalLife Scientific Wellness Center (VSWC), Bangkok, Thailand. A total of 72 healthy adult individuals with total serum 25-(OH)D level of 20-29 ng/ml were invited to choose from the three available options, namely, (1) Hydro-Cell-Key (HCK®, Hepart AG, Switzerland) contains vitamin D3 2,000 IU, vitamin C 1,000 mg, vitamin E 166 mg, vitamin A 1 mg, coenzyme Q10 30 mg, natural carotenoids 8 mg, and citrus flavonoids 200 mg in granule formulation; (2) VTL-7 (VWSC) contains similar vitamins and minerals but in capsule formulation; and (3) placebo capsule (no supplement). The 36-Item Short-Form Health Survey (SF-36) was used to measure QOL at baseline, month 3 and 6. A generalized estimating equation (GEE) was used to compare the repeated-measure outcomes across the three groups. This study was registered at the Thai Clinical Trial Registration (TCTR20190205002) and approved by the Bumrungrad International Institutional Review Board (BI-IRB No.258-10-18PhFub)., Results: Both VTL-7 and HCK saw a significantly higher increase in vitamin D than placebo at months 3 and 6, i.e., VTL-7 from 25.15 ± 2.13 to 35.53 ± 6.11 ( p < 0.001) and 33.38 ± 6.89 ( p < 0.001); HCK from 24.25 ± 3.08 to 28.43 ± 5.93 ( p = 0.005) and 27.40 ± 5.24 ( p = 0.012); and placebo from 24.00 ± 2.73 to 23.05 ± 4.39 ( p = 0.273) and 22.30 ± 6.23 ( p = 0.200), respectively. Similarly, β-carotenoids of VTL-7 vs. HCK groups significantly increased from 0.88 ± 0.68 vs. 0.94 ± 0.55 at baseline to 3.03 ± 1.79 ( p < 0.001) vs. 1.09 ± 0.61 ( p = 0.125) and 3.26 ± 1.74 ( p < 0.001) vs. 1.15 ± 0.66 ( p = 0.064), respectively. These findings were corroborated through the GEE analysis. Other micronutrients at months 3 and 6 did not increase significantly from baseline in any group. The overall QOL among the three groups in terms of physical ( p = 0.560) and mental ( p = 0.750) health increased but was not statistically significant., Conclusion: The supplements of MVMM in capsule formulation increased the serum levels of some micronutrients to a higher extent than that of granule formulation. Participant adherence remains a potential confounder and should be further explored., Clinical Trial Registration: identifier: TCTR20190205002., Competing Interests: PI was employed by Asia Global Research Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Jittat, Pongpirul, Tepwituksakit, Iammaleerat, Heath, Lungchukiet, Taechakraichana and Charukitpipat.)
- Published
- 2022
- Full Text
- View/download PDF
8. Neovaginal and Anal High-Risk Human Papillomavirus DNA Among Thai Transgender Women in Gender Health Clinics.
- Author
-
Uaamnuichai S, Panyakhamlerd K, Suwan A, Suwajo P, Phanuphak N, Ariyasriwatana C, Janamnuaysook R, Teeratakulpisarn N, Vasuratna A, and Taechakraichana N
- Subjects
- Adult, DNA, Female, Humans, Papillomaviridae genetics, Thailand epidemiology, Alphapapillomavirus, Papillomavirus Infections diagnosis, Papillomavirus Infections epidemiology, Transgender Persons, Uterine Cervical Neoplasms
- Abstract
Background: Although human papillomavirus (HPV)-related lesions in the neovagina of transgender women have been well documented, information on high-risk HPV (hrHPV) in the neovagina has been very limited. The objective of this study was to determine hrHPV DNA detection rate in the neovagina of transgender women., Methods: Neovaginal and anal swab were collected in liquid-based cytology fluid from transgender women visiting Gender Health Clinic and Tangerine Community Health Clinic in Bangkok, Thailand. Samples were processed for hrHPV DNA (reported as subtypes 16 and 18 or the pooled result of subtypes 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) by automated real-time polymerase chain reaction and for neovaginal cytology according to the Bethesda system. Demographic data and sexual history were obtained, and physical examination was conducted. HIV status was obtained from existing medical records., Results: Samples were collected from 57 transgender women (mean age, 30.4 years [interquartile range, 8 years]). From 35 of 57 valid neovaginal samples, 8 (20%) tested positive for hrHPV DNA. From 30 of 57 valid anal samples, 6 (19.4%) tested positive for hrHPV DNA. HIV status was known for 52 transgender women, 1 of which were HIV infected; neovaginal hrHPV was invalid in that patient., Conclusions: One of 5 transgender women visiting sexual health clinics in Bangkok was found to have hrHPV DNA in neovaginal and anal compartments. Studies are needed to look at incidence and persistence of hrHPV infection to inform anogenital precancerous and cancerous screening programs for transgender women., Competing Interests: Conflict of Interest and Sources of Funding: This research was funded by the Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University (grant number RA61/064). The authors declare no conflict of interest., (Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
9. Comparison of an oncology clinical decision-support system's recommendations with actual treatment decisions.
- Author
-
Suwanvecho S, Suwanrusme H, Jirakulaporn T, Issarachai S, Taechakraichana N, Lungchukiet P, Decha W, Boonpakdee W, Thanakarn N, Wongrattananon P, Preininger AM, Solomon M, Wang S, Hekmat R, Dankwa-Mullan I, Shortliffe E, Patel VL, Arriaga Y, Jackson GP, and Kiatikajornthada N
- Subjects
- Artificial Intelligence, Humans, Neoplasm Staging, Thailand, Therapy, Computer-Assisted, Clinical Decision-Making, Decision Support Systems, Clinical, Medical Oncology, Neoplasms therapy
- Abstract
Objective: IBM(R) Watson for Oncology (WfO) is a clinical decision-support system (CDSS) that provides evidence-informed therapeutic options to cancer-treating clinicians. A panel of experienced oncologists compared CDSS treatment options to treatment decisions made by clinicians to characterize the quality of CDSS therapeutic options and decisions made in practice., Methods: This study included patients treated between 1/2017 and 7/2018 for breast, colon, lung, and rectal cancers at Bumrungrad International Hospital (BIH), Thailand. Treatments selected by clinicians were paired with therapeutic options presented by the CDSS and coded to mask the origin of options presented. The panel rated the acceptability of each treatment in the pair by consensus, with acceptability defined as compliant with BIH's institutional practices. Descriptive statistics characterized the study population and treatment-decision evaluations by cancer type and stage., Results: Nearly 60% (187) of 313 treatment pairs for breast, lung, colon, and rectal cancers were identical or equally acceptable, with 70% (219) of WfO therapeutic options identical to, or acceptable alternatives to, BIH therapy. In 30% of cases (94), 1 or both treatment options were rated as unacceptable. Of 32 cases where both WfO and BIH options were acceptable, WfO was preferred in 18 cases and BIH in 14 cases. Colorectal cancers exhibited the highest proportion of identical or equally acceptable treatments; stage IV cancers demonstrated the lowest., Conclusion: This study demonstrates that a system designed in the US to support, rather than replace, cancer-treating clinicians provides therapeutic options which are generally consistent with recommendations from oncologists outside the US., (© The Author(s) 2021. Published by Oxford University Press on behalf of the American Medical Informatics Association.)
- Published
- 2021
- Full Text
- View/download PDF
10. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial.
- Author
-
Bumphenkiatikul T, Panyakhamlerd K, Chatsuwan T, Ariyasriwatana C, Suwan A, Taweepolcharoen C, and Taechakraichana N
- Subjects
- Administration, Intravaginal, Aged, Atrophy drug therapy, Double-Blind Method, Dyspareunia pathology, Estrogens, Conjugated (USP) therapeutic use, Female, Humans, Middle Aged, Prospective Studies, Tablets therapeutic use, Thailand, Treatment Outcome, Vagina pathology, Vulva pathology, Dyspareunia drug therapy, Estrogens, Conjugated (USP) administration & dosage, Female Urogenital Diseases drug therapy, Postmenopause drug effects, Tablets administration & dosage, Vulva drug effects
- Abstract
Background: Female sexual dysfunction (FSD) is prevalent in women with genitourinary syndrome of menopause (GSM). Vaginal estrogen is effective GSM treatment. This study was primarily aimed to evaluate the effects of vaginal administration of conjugated estrogens tablet on postmenopausal FSD using the Female Sexual Function Index (FSFI). Secondary aims were to evaluate vaginal pH, Vaginal Maturation Value (VMV), Normal Flora Index (NFI) and Most Bothersome Symptoms (MBS) changes., Methods: A double-blind trial was conducted in postmenopausal women with FSD (FSFI ≤26.55). Sixty-seven participants were randomized into two arms; vaginally administered conjugated estrogens tablet (0.625 mg, daily for 3 weeks then twice weekly for 9 weeks, n = 33), or placebo (n = 34)., Results: There was no significant improvement of FSFI observed in estrogens arm compared to placebo in each domain and overall index (p = 0.182). The estrogens significantly improved vaginal pH and VMV, toward more acidity (p = < 0.001), higher VMV (p = < 0.001) and more superficial cells (p = < 0.001). We observed no significant difference in NFI and MBS between arms (p = 0.282, 0.182)., Conclusion: We found no significant changes in FSFI, NFI, and MBS, but significant improvement in vaginal pH and VMV in postmenopausal women with FSD treated with vaginally administered conjugated estrogens tablet. Few side-effects were reported., Trial Registration: Thai Clinical Trial Registry identification number TCTR20180219001 , prospectively registered since 2018-02-19 11:33:21.
- Published
- 2020
- Full Text
- View/download PDF
11. Effect of multivitamin on serum 25-hydroxy vitamin D level in postmenopausal women: A randomized, double-blind, placebo-controlled trial.
- Author
-
Khrutmuang D, Panyakhamlerd K, Chatkittisilpa S, Jaisamrarn U, and Taechakraichana N
- Abstract
Objectives: To determine the effects of multivitamin vitamin D 300 or 600 units on serum 25 hydroxyvitamin D (25(OH)D) level after 4 weeks of supplementation in postmenopausal women with vitamin D insufficiency., Study Design: Randomized double-blind, placebo-controlled trial., Methods: Postmenopausal women who had vitamin D insufficiency were recruited into the study. The participants were randomized to 3 groups of 4-week treatment period with multivitamin (GPO, Governmental Pharmacy Organization) 2 tablets (contained vitamin D2 amount 600 units), multivitamin 1 tablet (contained vitamin D2 amount 300 units) or placebo. At baseline and after 4 weeks of supplementation, serum 25(OH)D were determined with electrochemilumines-cence immunoassay (Cobas, Roche Diagnostics) and level change of 25(OH)D level were compared among the groups., Results: Out of 144 participants, 49.3% had vitamin D deficiency (<20 ng/ml) and 50.7% had vitamin D insufficiency (<30 ng/ml). However, after 4 weeks of the GPO oral multivitamin, serum 25(OH)D levels significantly increased from 19.4 ± 6.3 ng/ml at baseline to 22.2 ± 5.2 ng/ml (p = 0.01) and from 19.5 ± 5.0 ng/ml to 23.3 ± 5.2 ng/ml (p < 0.01) in the groups receiving vitamin D 300 IU and 600 IU/day, respectively. Approximately, 10% of those who took vitamin D had serum 25(OH)D level above the insufficiency level within 4 weeks. There was no significant changes of serum 25(OH)D after 4 weeks in the placebo group., Conclusions: Daily supplementation of the generic multivitamin containing vitamin D2 300 and 600 IU daily for 4 weeks significantly increased mean serum 25(OH)D from baseline up above the deficiency level.
- Published
- 2016
- Full Text
- View/download PDF
12. Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women.
- Author
-
Tungmunsakulchai R, Chaikittisilpa S, Snabboon T, Panyakhamlerd K, Jaisamrarn U, and Taechakraichana N
- Subjects
- Double-Blind Method, Female, Humans, Middle Aged, Testosterone administration & dosage, Testosterone therapeutic use, Libido physiology, Postmenopause physiology, Sexual Behavior drug effects, Sexual Dysfunction, Physiological drug therapy, Testosterone analogs & derivatives
- Abstract
Background: Adding testosterone to hormonal therapy could improve sexual function and general well-being among women during climacteric. We evaluated the effectiveness of testosterone undecanoate on sexual function in postmenopausal women utilizing the standardized questionnaire FSFI score., Methods: Postmenopausal women with sexual complaints and Female Sexual Function Index (FSFI) ≤ 26.5 were enrolled in to this randomized, double-blinded, placebo-controlled trial. Participants were randomly assigned to 8-week treatment with either oral testosterone undecanoate 40 mg or placebo twice weekly with daily oral estrogen. The FSFI scores before and after treatment were compared to assess any improvement of sexual function., Results: Seventy women were recruited of which each group had 35 participants. The baseline characteristics and baseline FSFI scores were comparable between both groups. After 8 weeks of treatment, the FSFI scores significantly improved in both groups when compared to the baseline but the FSFI scores from the testosterone group were significantly higher than in the placebo group post-treatment (28.6 ± 3.6, 25.3 ± 6.7, respectively, p = 0.04). There was no difference in adverse effect between the two groups, Conclusions: The twice weekly addition of testosterone undecanoate to daily oral estrogen was associated with a significant improvement in sexual function among postmenopausal women than the use of the estrogen alone., Trial Registration: ClinicalTrials.gov Identifier NCT01724658 (February 17, 2012).
- Published
- 2015
- Full Text
- View/download PDF
13. Inter-correlation of knowledge, attitude, and osteoporosis preventive behaviors in women around the age of peak bone mass.
- Author
-
Puttapitakpong P, Chaikittisilpa S, Panyakhamlerd K, Nimnuan C, Jaisamrarn U, and Taechakraichana N
- Subjects
- Adult, Bone Density, Cross-Sectional Studies, Educational Status, Humans, Information Seeking Behavior, Male, Social Class, Surveys and Questionnaires, Thailand, Young Adult, Health Behavior, Health Knowledge, Attitudes, Practice, Osteoporosis prevention & control
- Abstract
Background: As silent and preventable in nature, postmenopausal osteoporosis awareness should be raised among young women prior to an irreversible period of declining bone mass. We therefore decided to assess the inter-correlation of knowledge, attitude and osteoporosis preventive behaviors in women around the age of peak bone mass., Methods: A cross-sectional study was conducted in 430 women aged 20-35 years. The participants' knowledge, attitude and behaviors concerning osteoporosis prevention were assessed along with demographic data using a four-part questionnaire. The items in this questionnaire were established by extensive literature review, including the Guideline for Management of Osteoporosis of the Thai Osteoporosis Foundation (TOPF) 2010. The content was validated by experts in osteoporosis and reliability was obtained with a Cronbach's alpha score of 0.83., Results: The mean age of women in this study was 29.4 ± 4.6 years. Half of the participants (49.5%) had heard about osteoporosis, mostly from television (95.3%, n = 203/213) and the internet (72.8%, n = 155/213). Most women had certain knowledge (85.2%) and positive attitude towards osteoporosis (53.3%). Nevertheless, 80% of the studied population did not have appropriate osteoporosis behaviors. We found significant correlation between the level of attitudes and osteoporosis behaviors (adjusted odd ratio = 3.3 with 95% confidence interval of 1.9-5.7); attitude and educational level (adjusted odd ratio = 2.2 with 95% confidence interval of 1.4-3.4); and attitude and knowledge (adjusted odd ratio = 3.5 with 95% confidence interval of 1.8-6.8)., Conclusion: Despite having certain knowledge about osteoporosis, the young women did not seem to have appropriate osteoporosis preventive behaviors. Developing a right attitude towards osteoporosis may be a key determinant to improving health practices in order to prevent osteoporosis.
- Published
- 2014
- Full Text
- View/download PDF
14. Final Declaration of the Asian Metaforum on the Role of Vitamin D and the Management of Osteoporosis.
- Author
-
Chan SP, Chen JF, Chu LW, Van DP, Hosking D, Ip TP, Koh L, Kung A, Lai NS, Lau E, Lee JK, Leewattana R, Min YK, Nghia ND, Boonsong O, Park HM, Ringe J, Setyohadi B, Shin CS, Soontrapa S, Taechakraichana N, Tanjung F, Tobing D, Tsai KS, Woo J, and Yang RS
- Subjects
- Accidental Falls prevention & control, Adult, Asia, Female, Humans, Male, Osteoporosis drug therapy, Osteoporosis therapy, Vitamin D therapeutic use, Vitamin D Deficiency drug therapy
- Abstract
Background: Vitamin D is essential for Ca absorption, prevention of falls and fracture, and maintenance of muscle strength and balance. Lack of awareness of the importance of vitamin D in bone health is common in Asia., Objective: To define key statements, objectives and actions for improving osteoporosis management and vitamin D inadequacy in Asia., Results and Conclusion: This declaration was jointly produced by specialists at the Asia Metaforum on the Role of Vitamin D and the Management of Osteoporosis, held in September 2006 in Hong Kong, to define actions to prevent vitamin D insufficiency in Asia. Although developed specifically for Asia, some or all of these statements may be applicable to other regions of the world.
- Published
- 2009
- Full Text
- View/download PDF
15. Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women.
- Author
-
Kung AW, Chao HT, Huang KE, Need AG, Taechakraichana N, Loh FH, Gonzaga F, Sriram U, Ismail NM, Farooqi A, Rachman IA, Crans GG, Wong M, and Thiebaud D
- Subjects
- Asian People, Bone Density drug effects, Cholesterol, HDL blood, Cholesterol, LDL blood, Estrogen Antagonists adverse effects, Female, Humans, Lumbar Vertebrae, Middle Aged, Osteoporosis ethnology, Postmenopause, Raloxifene Hydrochloride adverse effects, Triglycerides blood, Estrogen Antagonists administration & dosage, Osteoporosis prevention & control, Raloxifene Hydrochloride administration & dosage
- Abstract
In healthy Caucasian postmenopausal women, raloxifene increases bone mineral density (BMD), decreases biochemical markers of bone turnover, and lowers low-density lipoprotein (LDL) cholesterol, without effects on high-density lipoprotein (HDL) cholesterol and triglycerides. This randomized, double-blind study examines the effects of raloxifene 60 mg/d (n = 483) or placebo (n = 485) in healthy postmenopausal Asian women (mean age 57 yr) from Australia, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, Taiwan, and Thailand. Serum osteocalcin, serum N-telopeptide, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were assessed at baseline and 6 months. Lumbar spine BMD was measured at baseline and 1 yr in 309 women from 4 countries. Clinical adverse events were recorded at each interim visit. At 6 months, raloxifene 60 mg/d significantly decreased osteocalcin, N-telopeptide, total cholesterol, and LDL cholesterol by medians of 15.9%, 14.6%, 5.3%, and 7.7%, respectively, from placebo. Changes in HDL cholesterol and triglycerides were similar between raloxifene and placebo. Raloxifene 60 mg/d increased mean lumbar spine BMD (1.9%) from placebo at 1 yr (P = 0.0003). The incidences of hot flashes (placebo 3.5%, raloxifene 5.6%, P = 0.12), and leg cramps (placebo 2.7%, raloxifene 4.3%, P = 0.16) were not different between groups. No case of venous thromboembolism was reported. The effects of raloxifene 60 mg/d on bone turnover, BMD, and serum lipids in healthy postmenopausal Asian women were similar to that previously reported in Caucasian women.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.